Pulling ‘hormone balance’ apart
‘Balance’ sounds lovely. I still want to know which problem we're talking about.
A symptom is a better starting point
A hormone menu can sound like a list of settings to turn up or down. I want a few missing words filled in: which hormone, for which concern, and what improvement is expected? Otherwise ‘balance’ is doing all the work.
There can be real help behind a less glamorous description. FDA describes menopausal hormone therapy as an option for hot flashes and vaginal dryness. Those are things you can name and discuss. Getting older doesn't have to be cast as a failure for the symptoms to matter.
Menopause care comes with trade-offs
Hormone therapy isn't suitable for everyone. FDA describes risks alongside symptom relief. I want those risks in the same conversation as the possible relief, with room for medical history and alternatives.
Compounded hormones are medicines mixed to order, rather than ready-made products. Compounded medicines are not FDA-approved. I read FDA's advice on custom-mixed hormones alongside the symptom and risk information. A reassuring description of an ingredient isn't a safety finding.
I look for an explanation I can repeat in ordinary words: the symptom, the likely benefit and a risk. If every answer returns to being younger, the original concern has slipped out of the conversation.
Testosterone needs a diagnosis
For low testosterone, a single test isn't the whole diagnosis. The Endocrine Society describes symptoms alongside low results on at least two early-morning blood tests. I wouldn't let a colourful chart stand in for that assessment.
As of October 2026, the Society also says testosterone isn't approved to improve appearance or prevent problems linked to ageing. Treatment can reduce sperm production and raise the red-blood-cell count. Those points deserve space beside the hoped-for changes.
I can't tell from a menu whether treatment fits you. That's a personal assessment with a licensed clinician. A useful description makes that clear rather than treating an attractive list of outcomes as a diagnosis.
What I would want left on the page
Which symptom would count as improving? What would make the plan change? Could further assessment, another treatment or no hormone treatment be the answer? Those are questions I'd keep in front of me.
A licensed U.S. clinician can discuss symptoms and FDA-approved options where appropriate. Sermorelin, a peptide that prompts growth-hormone release, has its own evidence to explain. It doesn't inherit a proven longevity benefit from other hormone treatments.
Reading dated October 27, 2026. Sources and their limits.